LOS ANGELES--(BUSINESS WIRE)--CHA-Hollywood Presbyterian Medical Center (CHA-HPMC), a subsidiary of CHA Bio Group (a Korea-based global leader in bio-technology and health care) has introduced its latest addition, da Vinci Xi Surgical System. CHA-HPMC will be the first community medical center in the area (Hollywood, Korea Town, Los Feliz, and Silver Lake) to offer this advanced surgical system, which optimizes clinical outcomes and patient experience — while minimizing surgical invasiveness and the length of hospital stay.
“Bringing this multi-million dollar robotic surgery program to CHA-HPMC is a first critical step towards achieving our long-term vision of becoming a premiere medical center,” said Dr. Joung H. Lee, a neurosurgeon and Chief Administrative Officer at CHA-HPMC, who was recruited from the Cleveland Clinic after his 21-year tenure.
CHA-HPMC is not the only affiliate of the CHA Bio Group to utilize this technology. CHA Bio Group first introduced the robotic surgical system at its CHA Bundang Medical Center in 2013. Since its inception, over 3,400 surgical procedures were successfully conducted in the specialties of gynecology, urology, thoracic surgery, and surgical oncology.
Earlier this year, CHA-HPMC embarked on its $400 million master plan slated for completion by the end of 2020. Part of this plan are 2 new buildings: A 5-story patient tower equipped with the latest technology, 10-story building with 7 floors for parking, and top 3 floors dedicated for medical office spaces. Along with the campus expansion, strategic plans are in place to recruit world-class specialists in various areas, to fulfill the CHA Bio Group’s commitment to provide the highest quality care to our entire community and beyond.
Find out more about robotic surgery at www.hollywoodpresbyterian.com/.
About CHA-Hollywood Presbyterian Medical Center (www.hollywoodpresbyterian.com/)
CHA-HPMC has been an indispensable partner and resource within the Hollywood community since its founding in 1924. It is a community-based, safety-net, general acute care hospital with 434-licensed beds and operates intensive care unit, telemetry unit, acute rehabilitation unit, labor and delivery/obstetrics unit, 24-hour emergency department, surgical operating rooms, and 89-bed skilled nursing facility. Its diverse medical staff, which pledges quality care with compassion and respect, includes more than 500 physicians in 69 specialties — representing over 75 countries. With a workforce of more than 1,300 employees, CHA-HPMC is one of Hollywood’s Top-10 employers.
CHA-HPMC has been nationally recognized with the following quality awards from Healthgrades: Patient Safety, Labor and Delivery, Obstetrics and Gynecology, Back Surgery, Hip Fracture Treatment, and Treatment of Heart Failure.
About CHA Bio Group
CHA Bio Group (www.en.chamc.co.kr), headquartered in Pan-gyo, Korea, is a global leader in the biotechnology industry, consisting of 25 hospitals & clinics, 27 research & 7 education institutions, and 28 bio/pharmaceutical/healthcare companies. Its healthcare subsidiary, CHA Health Systems, delivers world-class care in all facets of medicine — famous particularly for its research and clinical work in the fields of fertility and cutting edge therapies using cord blood stem cells and immune cells.
